29 February 2024

International Pharmaceutical Aerosol Consortium

ADOPTION OF THE F-GAS REGULATION: IPAC WELCOMES THE GRADUAL PHASEDOWN OF HFCS WHILE STRESSING THAT PATIENT NEEDS MUST CONTINUE TO BE MET

The International Pharmaceutical Aerosol Consortium (IPAC) welcomes the recent adoption of the revision of the EU Fluorinated Gases (F-GAS) Regulation. We acknowledge that the final text of the Regulation is the result of almost two years of analysis of the proposal and negotiations among EU co-legislators, as well as exchanges between policymakers and stakeholders. IPAC believes that the adopted text brings the EU closer to achieving its visions of the European Green Deal and Climate Law and is particularly pleased with the higher quota allocation provided for medical inhalers (MDIs) until 2030, which better provides for continued patient access to MDIs while allowing manufacturers to transition to gases with lower GWP. IPAC also welcomes the inclusion of the European Medicines Agency (EMA) among the stakeholders that will be regularly consulted on the implementation of the Regulation. This is imperative to ensure that the specificities of MDIs – and the medical sector more broadly – are taken into account and to effectively monitor and prevent shortages of essential therapies for patients.

Many people living with respiratory conditions, such as asthma and COPD, rely on inhalers to lead healthy, active lives by managing their condition and relieving their symptoms. IPAC stresses the importance of centering patients' needs during future reviews of the Regulation, such as the 2028 and 2040 planned reviews. These evaluations will be instrumental in determining the need for medical HFCs in view of the 2050 phase-out, which would bring unintended consequences to patients' access to essential therapies.

IPAC members are investing in finding solutions to continue helping millions of people living with respiratory conditions and are preparing to comply with the newly introduced measures of the Regulation. This includes meeting the phase-down of HFCs by 2030 by advancing the transition to gases with lower global warming potential, as well as reporting and labelling obligations. We remain committed to our mission of meeting environmental and sustainability goals, and we look forward to continuing our collaboration with relevant Institutions to ensure the smooth implementation of this legislation.

ABOUT IPAC

(IPAC) is comprised of AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, GSK, Kindeva, Organon and Teva. IPAC members produce MDIs in Europe and supply MDIs to patients worldwide. IPAC's mission is to ensure that environmental policies relevant to inhaled therapies are patient-centric and appropriately balance both patient care and sustainability objectives. IPAC has developed principles to help guide policy discussions that reflect the lessons learned in our work on the Montreal Protocol on Substances that Deplete the Ozone Layer.

For more information, please visit IPAC's website at www.IPACinhaler.org

EU Transparency Register No. 602537137644-70

Contacts: Maureen Hardwick (+1 301 980 7837; info@ipacinhaler.org) and Caroline Vogt (+32 473 33 59 65; info@ipacinhaler.org)